Archive forOctober, 2009

Swine Flu becomes National Emergency


October 24, 2009

Obama Declares Swine Flu a National Emergency

By THE ASSOCIATED PRESS

Filed at 11:23 a.m. ET

WASHINGTON (AP) — President Barack Obama has declared the swine flu outbreak a national emergency.

The White House on Saturday said Obama signed a proclamation that would allow medical officials to bypass certain federal requirements. Officials described the move as similar to a declaration ahead of a hurricane making landfall.

               swineflu

Swine flu is more widespread now than it’s ever been and has resulted in more than 1,000 U.S. deaths so far.

Health authorities say almost 100 children have died from the flu, known as H1N1, and 46 states now have widespread flu activity.

The White House said Obama signed the declaration on Friday evening.

Comments

Center for Medicare and Medicaid Services info on H1N1

Medicaid and the Children’s Health Insurance Program (CHIP) Coverage of the 2009 H1N1Flu Vaccine and Treatment

The 2009 H1N1 flu (sometimes referred to as “swine flu”) is caused by a new strain of influenza virus. It is causing illness in people. The virus spreads from person-to-person, probably in much the same way that regular seasonal flu viruses spread.The symptoms of the 2009 H1N1 flu are similar to the symptoms of regular seasonal flu.These symptoms include fever, cough, sore throat, runny or stuffy nose, body aches,headache, chills, and fatigue. A significant number of people who have been infected with the 2009 H1N1 flu virus also have reported diarrhea and vomiting.

If you have flu-like symptoms, call your doctor’s office right away.

 Is there a vaccine for the 2009 H1N1 flu, like there is for the seasonal flu? Yes. The initial doses of the 2009 H1N1 flu vaccine are currently available for those at highest risk for infection. Additional doses are scheduled for shipment each week.Who should get the 2009 H1N1 flu vaccine?


There are some groups of people who have a higher risk of getting the 2009 H1N1 flu than others. Therefore, the Centers for Disease Control and Prevention (CDC) has recommended that the following groups get their vaccine as soon as it becomes available in their area:

•Pregnant women •People who live with or care for children younger than 6 months of age•Healthcare and emergency medical services personnel•Persons between the ages of 6 months through 24 years•People ages 25 through 64 years who are at higher risk because of chronic health disorders or weakened immune systems

If you aren’t in one of the groups listed above, talk with your doctor about when to get the vaccine.

Note: If you are sick and need to be in close contact with someone who has a higher risk of getting the 2009 H1N1 flu, consider wearing a surgical mask or cover your nose and mouth with a tissue. Remember to wash your hands frequently.

Will Medicaid and the Children’s Health Insurance Program (CHIP) cover the 2009 H1N1 flu vaccine?

Yes. Medicaid and CHIP cover the 2009 HIN1 flu vaccine.Medicaid and CHIP will cover both a single dose of the seasonal flu vaccine and one or more doses of the 2009 H1N1 flu vaccine, if more than one dose is needed.

Talk to your doctor to find out how many doses you will need. Children and pregnant women will get the vaccine free of charge. Adults are covered if they get the vaccine at a public health department, physician office, Federally-qualified health center, or rural health clinic, but they may have to pay a small copayment.

You may get the vaccine at a hospital, but it’s only recommended if you can’t get to another site.

Your state is working with your local public health department to make it easy for you to get a vaccine. To find the most convenient site for you, call or visit your state’s public health department Web site. A listing of state public health departments can be found by visiting www.cdc.gov/h1n1flu/states.htm.

What if I get the 2009 H1N1 flu? Contact your doctor for advice on how to treat the 2009 H1N1 flu.
Medicaid and CHIP will cover your care, including an evaluation, any required tests, and your treatment. Children under 18 and pregnant women will get care free-of-charge while other adults may have to pay a small copayment.
There are drugs your doctor may prescribe for treating both seasonal and H1N1 flu called “antiviral drugs.” These drugs can make you better faster and may also prevent serious complications. This flu season, antiviral drugs are being used mainly to treat people who are very sick, such as people who need to be hospitalized, and to treat sick people who are more likely to get serious flu complications. Remember, most people with the 2009 H1N1 flu have had mild illness and haven’t needed medical care or antiviral drugs, and the same is true of seasonal flu.

Some states have preauthorization requirements for antiviral medications, such as Tamiflu or Relenza. This means that the prescription must be approved by the State where you live. This approval process can take 24 hours. If you are prescribed an antiviral medication, you are entitled to get at least 3 days worth of the prescription right away. The CDC recommends a full 5-day course of antiviral medication, so if you are unable to get 5 days worth of the prescription right away, make sure to go back to the pharmacy after 24 hours to pick up the rest.

Where can I find more information about the 2009 H1N1flu, including how the virus is spread and how to prevent it?

For more information about the 2009 H1N1 flu, visit www.flu.gov or the Centers for Disease Control Web site at www.cdc.gov/h1n1flu/general_info.htm. You can also call 1-800-CDC-INFO (1-800-232-4636) for more information.Where can I find out more about Medicaid or CHIP?


Call your State Medical Assistance (Medicaid) office for more information. Call 1-800-MEDICARE (1-800-633-4227) and say “Medicaid” to get the telephone number for your State Medical Assistance office. TTY users should call 1-877-486-2048. You can also visit www.medicare.gov.

Will Medicare cover the 2009 H1N1 flu vaccine? Yes. Medicare will cover administration of the 2009 H1N1 flu. Your doctor or healthcare provider can’t charge you for the 2009 H1N1 vaccine because they received thevaccine for free.You pay nothing for the 2009 H1N1 vaccine’s administration if your doctor or health careprovider accepts assignment. Assignment means that your doctor, provider, or supplier hassigned an agreement with Medicare to accept the Medicare-approved amount as full payment for covered services. The Part B deductible and coinsurance don’t apply to the2009 H1N1 vaccine or its administration.

Where can I find out more about Medicare?

For more information about Medicare, visit www.medicare.gov. You can also call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048.

Comments

Where are the flu shots right now?

This is the best site for all you ever wanted to know about the Swine flu.  www.Flu.gov

There is a map with a drop down menu by state so that you can find out IF the vaccine is available, where it is, and if not, when it will be.

If you THINK you have the flu, it lists all of the symptoms.

If you want to avoid the flu, it gives handy tips.

If you have kids who want to know more- then Elmo can help explain.

10_07_elmo_rosita_thumbnail_spanish

It debunks false claims and fears.  See the section called Myths and Facts.

It warns of internet shopping for the vaccine.

ANYTHING you ever wanted to know about the H1N1 is located here.  Can your pet get it from you?   Find out.

Ask the expert? 

askexpert

Find out what illnesses or disease groups should and should not get this vaccine.

Again,

Go to www.Flu.gov for all of this valuable info

Comments

PIDD Patients and Swine Flu Shots

Swine Flu Shots Safe for People With Weak Immune Systems: Experts

Another study outlines risks of catching H1N1 from various routes

HealthDay
Friday, September 18, 2009

HealthDay news imageFRIDAY, Sept. 18 (HealthDay News) — The H1N1 swine flu vaccines approved this week by the U.S. Food and Drug Administration can be safely used by people with compromised immune systems, according to new recommendations from the American Academy of Allergy, Asthma & Immunology.

These would include people whose immune responses are weakened by medical treatments (such as for cancer or organ transplant) and those infected with HIV, the experts said.

Influenza vaccines can be made from live — but modified and weakened — virus, or they can be made from the harmless byproducts of the virus (so-called “killed” virus vaccines). According to the experts at the American Academy of Allergy, Asthma & Immunology (AAAAI), all of the injected H1N1 vaccines so far approved by the FDA are of the “killed” variety.

“There’s never any harm with giving killed influenza vaccine” to immuno-compromised individuals, said Dr. Kenneth Bromberg, director of the Vaccine Research Center at The Brooklyn Hospital Center in New York City.

There is one vaccine out there that those with weakened immune systems should avoid: the nasal spray form of the flu vaccine, FluMist. FluMist is already available as a seasonal flu vaccine, and 3.4 million doses of an H1N1 version of FluMist are expected to be distributed nationally the first week of October, CDC officials announced Friday.

FluMist is derived from live (but very weakened) virus, so it could pose a problem for people with poor immune systems. The recommendation to avoid FluMist extends to people living in close proximity to an immune-compromised person, such as family members, because they could pass on the live virus to that individual, the AAAAI said.

No such threat exists for average Americans with robust immune responses, the experts said.

One question for some people with compromised immune systems is whether the flu shot will actually help them, given their poor immune defenses.

People with so-called “primary” immune deficiency — rare immune deficiencies inherited at birth — can take the H1N1 vaccine, the academy said. “Although the antibody response may be poor or low [in these individuals], the cell-mediated response may be a helpful immune response to [fight] the virus,” AAAAI President-elect Dr. Mark Ballow said in a news release issued Thursday.

But, depending on their level of immune cell function, certain HIV-infected individuals may not be able to mount enough of an immune response to make flu vaccination worthwhile, the experts said.

“The issue is whether the compromised immune response might result in insufficient protection, not whether the inactivated H1N1 or seasonal influenza vaccine is excessively harmful,” said Dr. Paul Greenberger, president of AAAAI.

“The CDC (U.S. Centers for Disease Control and Prevention) notes that most HIV patients can receive the immunization, and from earlier studies with seasonal flu shots, [it appears] there may be a reduced response if the number of CD4+ lymphocytes is less than 100/mm3,” Greenberger said. “Better responses occurred if patients had CD4+ lymphocyte counts of at least 400.”

He added that “studies haven’t been published yet of H1N1 vaccination in HIV patients.”

In other swine flu news, a study published in the September issue of the journal Risk Analysis seeks to quantify the risk from various routes of transmission of the swine flu virus. Researchers from the University of California, Berkeley, and the University of Illinois used sophisticated modeling and pored over the available data on four key means of person-to-person H1N1 transmission.

They speculate that hand contact with a contaminated surface brings a 31 percent risk of actual infection; inhaling tiny particles laden with virus in a room brings a 17 percent likelihood of infection; close contact where coughs spray viral-laden droplets onto the eyes, nostrils or lips brings a 52 percent chance of infection. Inhaling relatively large particles carrying virus when three feet or nearer to an infected person carries only a 0.52 percent risk for infection, the research team said.

According to the researchers, the study strengthens current recommendations to cover the mouth when coughing and to disinfect commonly touched surfaces.

SOURCE: Paul Greenberger, M.D., president, American Academy of Allergy, Asthma & Immunology; Kenneth Bromberg, M.D., director, Vaccine Research Center, The Brooklyn Hospital Center, New York City; Sept. 17, 2009, news release, American Academy of Allergy, Asthma & Immunology; Sept. 16, 2009, news release, Society for Risk Analysis

Comments

Characteristics of Swine Flu from the Washington Post

Swine Flu Characteristics Becoming More Evident
Links to Pneumonia, Rapid Effects on Young Noted

By Rob Stein
Washington Post Staff Writer
Saturday, October 17, 2009

As swine flu continues to spread around the globe, a clearer and in some ways more unnerving picture of the most serious cases has started to emerge, indicating that the virus could pose a greater threat to some young, otherwise vibrant people.

The virus can cause life-threatening viral pneumonia much more commonly than the typical flu, prompting the World Health Organization on Friday to warn hospitals to prepare for a possible wave of very sick patients and to urge doctors to treat suspected cases quickly with antiviral drugs.

Experts stress that most people who get the H1N1 virus either never get sick or recover easily. But some young adults, possibly especially women, are falling seriously ill at an unexpectedly rapid pace and are showing up in intensive care units and dying in unusually high numbers, they say.

Although why a minority of patients become so sick remains a mystery, new research indicates that H1N1 is different from typical seasonal flu viruses in crucial ways — most notably in its ability to penetrate deep into the lungs and cause viral pneumonia.

“It’s not like seasonal influenza,” Nikki Shindo of the World Health Organization said at the conclusion of a three-day meeting of more than 100 experts the WHO convened in Washington to review swine flu. “It can cause very severe disease in previously healthy young adults.”

Meanwhile, the Centers for Disease Control and Prevention reported Friday that vaccine production was proceeding more slowly than hoped. Officials had predicted that about 40 million doses would be available by the end of October, but that projection will probably fall short by about 10 million to 12 million doses, said Anne Schuchat, director of the CDC’s National Center for Immunization and Respiratory Diseases.

“Eventually, anyone who wants to be vaccinated will be able to be, but the next couple of weeks will continue to be a slow start,” she said. So far, 11.4 million doses have become available and states have ordered about 8 million doses, but the vaccine will not become available in large amounts until November, she said.

The WHO’s warning came as U.S. health officials reported that the number of states reporting widespread flu activity was up to 41, including Maryland and Virginia, and that the death toll among children had climbed to 86. Maryland has reported 10 deaths and Virginia health officials say eight people, including one child, have died. There have been no reports of deaths among District residents.

Swineflukids

So far, the virus does not seem to sicken or kill people more often than the typical flu. But the pattern of people getting seriously ill is far different than in typical flu seasons. The elderly, who are usually most vulnerable, are generally spared; children, teenagers, pregnant women and young adults are the most common victims.

Officials have been closely monitoring the virus for signs it has mutated into a more dangerous form, and they have also been testing animals for the virus because of fears that infected livestock could cause more-lethal mutations.

Federal agriculture officials said Friday that pigs from the Minnesota State Fair had tested positive for H1N1, which would make them the first documented pig infections in the United States, if follow-up tests confirm the results. But there are no signs that the pigs were sick or that the animals had infected any humans. Children staying near the fair had gotten the virus, but there was no sign they were infected by the pigs.

Seasonal flu viruses tend to infect primarily the upper respiratory system. But recent animal studies and autopsies on about 100 swine flu victims show that H1N1 infects both the upper respiratory tract, which makes it relatively easy to transmit, and also the lungs, which is more similar to the avian flu virus that has been circulating in Asia.

“It’s like the avian flu on steroids,” said Sherif Zaki, chief of Infectious Disease Pathology at the CDC. He noted that unusually large concentrations of the swine flu virus have been found in the lungs of victims: “It really is a new beast, so to speak.”

About a third of patients who required intensive care had bacterial pneumonia, but H1N1’s proclivity to infect lung cells makes it more likely than seasonal flu to cause viral pneumonia, which can lead to life-threatening lung damage.

“Remarkably different is this small subset of patients that presents very severe viral pneumonia,” Shindo said.

One of those patients was Karen Ann Hays of Sacramento, Calif., an otherwise healthy nurse whose hobby was tackling grueling triathlons. Despite desperate measures to keep her alive, Hays, 51, died in July within days of coming down with swine flu.

“I have seen more cases like this in the last three months than I have in the last 30 years,” said Peter Murphy, director of intensive care at the Mercy San Juan Medical Center in Carmichael, Calif., who tried to save Hays.

Although it remains unclear how frequently the virus makes people seriously ill, recent reports from Mexico, Canada, the United States, Australia and New Zealand indicate that perhaps 1 percent of patients who get infected require hospitalization. Between 12 to 30 percent of those hospitalized need intensive care, and 15 to 40 percent of those in intensive care die.

While about two-thirds of U.S. patients who were hospitalized in the spring had other medical conditions, the CDC reported this week that an analysis of more than 1,400 hospitalized victims found perhaps half had no serious health problems.

About one-third of those around the world who have died or became seriously ill from swine flu appear to have been vulnerable because they had heart or lung disease, chronic kidney problems, or other ailments that usually put people at risk. But others had conditions that many may not immediately associate with frailness, such as mild asthma, high blood pressure, high cholesterol and obesity.

“Many of these people look just like you or me,” said Anand Kumar, an associate professor of critical care and infectious disease at the University of Manitoba in Winnipeg, Canada, which was hit hard by the pandemic’s first wave last spring.

There appears to be no way to predict with certainty who may suffer serious, life-threatening complications, since some victims have had no other health problems.

For instance, Stacey Hernandez Speegle, 30, of Madison, Calif., who died in July, “was in great shape. She was on the softball team. She had two young children. She was renovating her house,” said her mother, Tamara Brooks. “It’s just so hard to believe.”

Although it has been well publicized that pregnant women appear to be at increased risk, some evidence has started to suggest that being female may itself be a risk factor, for reasons that remain unclear.

“There’s no question that women, and particularly young women, are getting hit disproportionately,” said Kumar. He noted that women tend to have more fat tissue, which can help stimulate a dangerous inflammatory response to infections.

And some of those who develop serious illness deteriorate soon after starting to feel ill. They require oxygen masks, ventilator machines to pump oxygen into their lungs to keep them alive, and drastic, often rarely used measures to try to save them within days of the first fever, ache or cough.

“The rapidity of it is striking,” said Andrew R. Davies, deputy director of intensive care at Alfred Hospital in Melbourne, Australia.

Some of the cases in Australia and New Zealand were so severe that doctors resorted to a much more aggressive, less commonly used treatment known as extracorporeal membrane oxygenation (ECMO). It involves siphoning patients’ blood into a machine to remove carbon dioxide and then infuse it with oxygen before returning it to their bodies.

“It’s quite an extreme form of treatment,” said Steve Webb, a clinical associate professor at the Royal Perth Hospital in Australia.

Other doctors have tried administering nitric oxide and putting patients in a bed that turns them upside down to help their lungs work better. “Our back was against the wall,” Murphy said, adding that after the deaths of patients such as Hays his hospital is working to make ECMO available.

“It’s very difficult to get this double-barreled message out that: ‘Yes, most cases are mild, but in a small percentage of cases these cases are disastrous,’ ” Vanderbilt University’s William Schaffner said. “But the message is: Don’t underestimate H1N1.”

Of the at least 86 Americans younger than 18 who have died from H1N1, 11 deaths were reported in the past week. About half of the deaths in the past month were among teenagers, Schuchat said. Since Aug. 30, 43 pediatric deaths have been reported, including three in those younger than age 2, five among those ages 2 to 4, 16 in those ages 5 to 11, and 19 among those ages 12 to 17, she said.

“These are very sobering statistics,” Schuchat said, noting that only about 40 or 50 children usually die during an entire flu season.

Virginia Health Commissioner Karen Remley said Friday that although the majority of H1N1 cases in the state are “mild and moderate,” significant numbers have become seriously ill.

In Maryland, at least 257 people have been hospitalized with confirmed cases of H1N1 since June, health officials said.

At least 2,914 Americans have died from flu-related illnesses since the H1N1 began, the CDC said.

Staff researcher Madonna Lebling and staff writer Michael Laris contributed to this report.

Comments

FLU VIEW

As you may have heard, the H1N1 Vaccine is running behind schedule right now.   Don’t forget, as PIDD patients, we should NOT take the live FluMist vaccine.   We can only have the dead shot that will be coming out later.  The unfortunate thing about the timeliness (or lack thereof) of the vaccine supply, is that the Flu is at epidemic levels RIGHT now, and by the time the vaccine comes out, we get it, and it takes effect- we may have already had the flu, or at least have been exposed to it.

So, good luck my friends.

This is from the CDC

2009 H1N1 Flu U.S. Situation Update
October 16, 2009, 7:30 PM ET

Map: Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists
(Activity levels indicate geographic spread of both seasonal and 2009 influenza A [H1N1] viruses)
(Posted October 16, 2009, 7:30 PM ET, for Week Ending October 10, 2009)

FluView, Week Ending October 10, 2009. Weekly Influenza Surveillance Report Prepared by the Influenza Division. Weekly Influenza Activity Estimate Reported by State and Territorial Epidemiologists. Select this link for more detailed data.

Comments

NEWS ABOUT PIDD RESEARCH

This is what Dr. Hans Ochs is working on at Seattle Children’s Hospital.

He is one of the top Dr’s who works on our behalf.

Dr. Hans Ochs

Seattle Children’s researcher Dr. Ochs is looking at the connection between immune deficiencies and genes.

Primary immune deficiency diseases (PIDD), an umbrella term referring to more than 130 genetic defects involving the immune system, affect as many as 500,000 Americans and 10 million people worldwide.

People with PIDD are unable to fight off bacteria, viruses, parasites, fungi and malignant cells, which can lead to frequent infections that are difficult to fight, and to an increased incidence of cancer.

PIDD is not contagious; it is hereditary — parents can pass it to their children. According to the Centers for Disease Control and Prevention (CDC), many primary immunodeficiencies are the result of a single gene defect.

The diseases can strike males and females of all ages, with the more severe immunodeficiency diseases usually detected most frequently in children.

Early diagnosis and treatment of PIDD is essential to prevent the infections from causing permanent damage, especially to the lungs. The condition can go undetected because the symptoms appear as “ordinary” infections of the sinuses, ears or lungs, or as gastrointestinal problems or inflammation of the joints.

As a result, families and physicians are often unaware that the troubling conditions they see in the child are actually caused by an underlying defect of the immune system.

Signs, Symptoms and Treatment of Primary Immune Deficiency Diseases

How do physicians know if a child has a primary immune deficiency disease? A pattern of recurring illnesses may be explained by an underlying PIDD.

According to the Jeffrey Modell Foundation, some warning signs of PIDD that physicians should look for include:

  • Eight or more new ear infections within one year
  • Two or more serious sinus infections within one year
  • Two or more months on antibiotics with little effect
  • Two or more pneumonias within one year
  • An infant’s failure to gain weight or grow normally
  • Recurrent deep-skin or organ abscesses
  • Persistent thrush in mouth or elsewhere on the skin after age 1
  • Need for intravenous antibiotics to clear infections
  • Two or more deep-seated infections
  • A family history of PIDD

Dr. Hans Ochs, professor of pediatrics at Seattle Children’s and the University of Washington, emphasizes that it’s important to know the family’s medical history.

“If a pregnant woman had a male sibling or other close male relatives who died prematurely of an infection or has other children with immune deficiencies, I’d recommend that the family be evaluated for a genetic form of PIDD and, if the disorder is X-linked, the woman undergo prenatal testing.

“That way we can take appropriate measures right after the baby is born. Also, some forms of PIDD diseases are associated with a tendency to bleed and the obstetrician may recommend a Caesarean section to prevent damage to the baby.”

Infections in a patient with PIDD can be chronic and severe and re-occur frequently. These infections tend to require prolonged therapy. Patients also may respond poorly to a conventional course of antibiotics.

The treatment for immunodeficient patients depends on the severity of the infections and other health problems and the specific genetic defect that is involved.

Most patients require aggressive treatment with antibiotics or antiviral agents. Some also benefit from regular (every two to four weeks) antibody replacement therapy (often referred to as IVIG therapy), which works by replacing the antibodies that the body cannot make on its own.

Finally, some patients require bone marrow transplant or other alternative treatments. In the future, gene therapy may also be a viable treatment option.

Progress Seen in PIDD Research

About 50 years ago, doctors developed a way to prevent infections by replacing antibodies via infusion of gamma globulin, a component of blood serum that is high in disease-fighting ability.

Gamma globulin from many donors is pooled and, in recent years, is administered intravenously or subcutaneously, giving the patient the antibodies he or she needs. However, this is a control measure, not a cure; PIDD patients may need infusions their entire lives.

In fact, about half of the patients the PIDD clinic sees are adults. “Many of these individuals would have died in childhood if it weren’t for antibiotics, IVIG or other treatments for infection,” said Dr. Ochs.

Seattle Children’s is one of only a few hospitals in the country researching and treating patients with PIDD and is a leader in developing new diagnostic techniques to combat PIDD.

By the early 1990s, Children’s researchers, such as Dr. Ochs and Dr. David Rawlings, head of Children’s Immunology division and associate professor of pediatrics and immunology at the University of Washington, were making the connection between immune deficiencies and genes.

New treatment possibilities

This opened new possibilities for treatment. Recent work at Children’s and elsewhere, coupled with improved methods for gene sequencing and the human genome project, has led to rapid acceleration in identification of the genetic basis of many previously unknown immune disorders.

In recent years, a team of Children’s researchers led by Drs. Ochs and Rawlings have helped open new treatment possibilities, such as gene therapy.

One important area of research focuses on removing stem cells from a patient, infecting the cells with a normal copy of the defective gene, and returning the stem cells to the patient.

“Most primary immune diseases begin in childhood, which means Children’s sees a lot of these kids,” said Dr. Rawlings. “As a result, we have developed an expertise no one else in the region has and we have become the referral center for children and adults with immune problems.

“We have genetic testing capabilities no one else has. We serve as an international center for prenatal and neonatal testing, and for testing of adults to identify carriers of immune deficiency disorders.”

Dr. Ochs is also the primary investigator for a $12 million grant administered by the U.S. Immune Deficiency Network (USIDnet), an international consortium of 50 researchers and specialists in the field.

The consortium studies PIDD, educates young investigators about the disease and administers, reviews and provides grants. It also funds registries to track the long-term health of patients and provides an anonymous repository that makes DNA or cell lines generated from selected patients available in order to study molecular defects of these diseases.

The Immune Deficiency Foundation (IDF) and the Jeffrey Modell Foundation, two organizations founded by parents of children affected by PIDD, both support research in Dr. Ochs’ laboratory in Children’s Division of Immunology.

Additionally, the Jeffrey Modell Foundation recently made available matching funds for an endowment for a fellowship in primary immunodeficiency disease.

Comments

PIDD and Swine Flu (H1N1) Recommendations from the IDF

The IDF has recommended the following for patients with Primary Immune Deficiency Disease who are concerned about the H1N1 Flu.

Please read carefully and take note:

                swinefluvaccine

H1N1-A (Swine flu) and Seasonal Influenza
Influenza, commonly known as the “flu”, is a contagious viral disease that typically occurs in the winter months and causes cough, fever, sore throat, headache, chills, muscle aches and fatigue. This year a new strain of influenza known as the Swine “flu” or H1N1-influenza has appeared, raising concerns that it might represent a much more serious illness than typical seasonal influenza. So far those fears have not been realized and the H1N1-A flu virus appears to cause an illness similar to that caused by the typical seasonal influenza virus. The H1N1-A virus has caused some deaths, just as does seasonal influenza. Some pregnant women as well as certain adults and children with significant underlying medical conditions have been reported to experience more serious infections than average. There is no experience or information available about the relative risk of H1N1 for patients with primary immunodeficiency diseases (PIDD). IDF hopes to survey PIDD patients this autumn to try to obtain data on this question.
Influenza (caused by both the H1N1-A and seasonal viruses) is transmitted from person to person by airborne droplets formed during coughing and sneezing. These droplets are inhaled or land on mucus membranes (lining of the nose or inside of the mouth) or the conjunctiva (the thin membrane that covers the surface of the eye). Influenza virus also can be transmitted orally. Good hygiene and frequent hand washing are important to prevent transmission. For most people, the “flu” lasts only a few days, but some people get much, much sicker. Influenza can lead to pneumonia and is of particular concern in people with pre-existing heart and/or lung conditions.
Prevention
Commonsense hygiene practices are critical in helping to limit the spread of the virus. The CDC recommends that patients refrain from returning to work or school until 24 hours after body temperature has returned to normal without fever-reducing medication. It is also recommended that all people cough into their elbows or sleeves, and wash their hands frequently.
The most effective way to avoid an infection with influenza is to receive the influenza vaccine annually. Influenza vaccines are safe and effective and, contrary to a common misconception, they do not cause the “flu”. Because the influenza virus characteristically changes or mutates from year to year, each year it is necessary to prepare a new vaccine for protection from the new “flu” strains that are present that year. For this reason it is essential that everyone get immunized against the seasonal “flu” every year because last year’s vaccine may not be protective against this year’s virus strains. Currently there are two different types of seasonal “flu” vaccine available in the US - the inactivated or “killed” “flu” vaccine (the flu shot) and a live attenuated influenza vaccine (nasal spray). Both are highly effective in preventing influenza in normal individuals.
This year a swine flu virus has mutated to allow that virus to cause disease in humans and, therefore, a new vaccine to protect against this mutant virus needed to be prepared. Because swine flu appeared after the seasonal “flu” vaccine for this year had already begun to be manufactured, a separate vaccine was needed. This year there are separate vaccines for the seasonal “flu” and the H1N1-A virus, so everyone receiving the seasonal influenza vaccine should also receive the H1N1-A vaccine.
The “Flu-Shot”
The most commonly used vaccine, often called the “flu shot,” is a killed virus vaccine that can be given to individuals ranging from 6 months to senior citizens. This inactivated vaccine can be used by everyone except individuals who have had an allergic reaction to eggs.
This traditional vaccine requires an injection and may cause local swelling and tenderness at the injection site. For children receiving the flu shot for the first time, two injections spaced about one month apart are required. These should preferably be given in September and October before the influenza season begins. In subsequent years, only a single vaccine dose is required. Unfortunately, children who only received a single dose of vaccine in the first year often do not develop protective immunity and two doses should be given to the child in the second year.
The vaccine for H1N1-A swine flu is now being manufactured and first doses should become available sometime in October 2009. Supplies will be limited initially and you should check with your doctor periodically to determine availability.
FluMist
The other vaccine is a live attenuated influenza virus (LAIV) vaccine that is administered by droplets given into the nose (FluMist). FluMist is the name given to the intranasal seasonal influenza virus vaccine. Attenuation means that the virus has been weakened so that it does not cause illness in normal healthy people.
FluMist is approved for individuals ranging from 2 to 49 years old. Administration does not require any injections. However, since it is a live virus vaccine, it has some theoretical risk for patients with defective immunity. It is the general recommendation that patients with T cell disorders, such as SCID and DiGeorge Syndrome, and B cell disorders with hypogammaglobulinemia/agammaglobulinemia, such as X-linked agammaglobulinemia and CVID not be given this form of influenza vaccine (FluMist). The IDF has reviewed this issue carefully with the FDA and the manufacturer of FluMist and hopes that additional studies will be conducted to help clarify the actual level of risk to our patient population. There seems little reason to expect that Flumist poses an increased risk for patients with CGD or complement disorders. Patients with HIV infection and immunodeficiency have been given this live agent vaccine without problem, but there have been no studies of patients with primary immunodeficiency.
As with any live virus vaccine, concern has been raised about the possible spread of the vaccine virus from an immunized person to a close contact such as a family member with PIDD. Studies looking for such spread in nursery schools where only some children received the FluMist found the level of spread to non-immunized classmates was very low. This observation gives us some reassurance that the risk of the spread of this agent from a FluMist immunized child or adult to an immunodeficient family member should also be low. Furthermore we are not aware of a single instance of a patient with PIDD developing influenza as a result of contact with a FluMist immunized individual, despite several million doses of this vaccine being used each year for the past several years. As a general recommendation only patients with the most severe forms of PIDD (babies with untreated SCID) should avoid contact with individuals recently immunized with FluMist.
The CDC Advisory Committee on Immunization Practices (ACIP) issued the following recommendation concerning FluMist (LAIV) use in individuals in close contact with patients with impaired immune systems. “The flu shot is preferred for people (including health-care workers and family members) in close contact with anyone who has a severely weakened immune system (requiring care in a protected environment, such as a bone marrow transplant unit). People in close contact with those whose immune systems are less severely weakened (including those with HIV) may get LAIV.” The live H1N1 vaccine should carry the same low level of risk as does the live seasonal influenza vaccine.
Primary Immunodeficiency Family Plan
Nevertheless, for families with a member who has PIDD, we recommend that all members of the family group should be given the inactivated (killed) vaccine for both the seasonal and H1N1 influenza. The vaccines usually become available in August or September. Studies have shown that immunization can still be effective when given well into February or March in some years, so it is important to ask for the vaccine even if the New Year has passed.
Why do we recommend that everyone be immunized? First, some patients with a primary immunodeficiency may benefit from the vaccine. Even if they don’t, there is little down side to receiving the inactivated vaccine. Family members who are able to respond to the vaccine will be protected (a good thing in its own right). Even if the patient with PIDD does not respond to the immunization, he/she will benefit from having everyone else in the family protected from infection and not susceptible to bringing the virus home with them. We want to create a “protective cocoon” of immunized persons surrounding our patients so that they have less chance of being exposed. It would be a good strategy to encourage employers to provide influenza immunization programs at the place of work and schools to similarly encourage immunization of the student body to further extend this “cocoon.”
Currently, the Immune Deficiency Foundation understands that individuals with PIDD have at least the same risk of contracting swine flu as does the rest of the population. The same type of anti-viral medicine, i.e. Tamiflu or Relenza, which is effective for people with normal immune systems, would be effective for patients with PIDD who get the H1N1 influenza. Note that IgG replacement therapy does not protect against the “flu”. Current IVIG or SCIG preparations also cannot be relied on to contain antibodies protective against swine “flu”.
Influenza can usually be diagnosed rapidly by a test done in physician offices. Unfortunately the test has proven to be unreliable in detecting the swine flu and therefore this year it is recommended that persons experiencing the symptoms of the flu go ahead and immediately get anti-virus treatment without waiting for a confirmative test. Speed is important in this situation since the antiviral medications are most effective if begun within 48 hours of the onset of the illness. It would be a good idea to discuss with your physician plans for dealing with influenza before you get sick so that you are prepared. If you do become ill you should contact your doctor immediately about initiating treatment. However, it would be wise to contact your physician first, before going to their office, an urgent care facility or emergency room.
During the “flu” season, you may want to stay away from crowded public places, such as shopping malls, if you are concerned about exposure. Most people can get information from the national media and from their physicians on other ways to prevent exposure, as well as when to use additional precautionary measures.
For more, updated information on the Swine Flu, go to the CDC Website:
http://www.cdc.gov/swineflu
For more information about the H1N1 Vaccine, see the CDC Website:
http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm
What do I do if there is seasonal or swine “flu” in the schools or at my workplace?
There is no single recommendation that is applicable to every situation. Some medical advisors recommend that unless H1N1 or seasonal flu is in their classroom, children with PIDD should go to school. If there is a known direct contact with secretions from a “flu”-affected (H1N1 or seasonal “flu”) child or adult by the PIDD child, that child should go on Tamiflu once a day for 10 days. If the PIDD child develops symptoms of influenza, that child should go on Tamiflu twice a day for 10 days. Relenza could also be used as the anti-viral treatment. The same treatment recommendations should apply to adults with CVID. As stated earlier, only patients with the most severe forms of PIDD (babies with untreated SCID) need to strictly avoid contact with individuals recently immunized with FluMist. If you have any questions, please contact your specialist.

Comments